RIPE-KG · Version 1.1.0 · Resource
ripekg:work/10.1016%2Fj.heliyon.2023.e23246
https://w3id.org/ripe/ripe-kg/work/10.1016%2Fj.heliyon.2023.e23246
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1016%2Fj.heliyon.2023.e23246Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccinesa prospective multi-center study |
prism:doi |
10.1016/j.heliyon.2023.e23246 |
ripekg:work/10.1016%2Fj.heliyon.2023.e23246Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccinesa prospective multi-center study |
dcterms:title |
Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccinesa prospective multi-center study |
ripekg:work/10.1016%2Fj.heliyon.2023.e23246Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccinesa prospective multi-center study |
rdf:type |
node1 |
ripekg:work/10.1016%2Fj.heliyon.2023.e23246Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccinesa prospective multi-center study |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1016%2Fj.heliyon.2023.e23246Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccinesa prospective multi-center study |
rdf:type |
rdfs:Resource |
ripekg:work/10.1016%2Fj.heliyon.2023.e23246Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccinesa prospective multi-center study |
rdf:type |
owl:Thing |
ripekg:work/10.1016%2Fj.heliyon.2023.e23246Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccinesa prospective multi-center study |
rdf:type |
prov:Entity |
ripekg:work/10.1016%2Fj.heliyon.2023.e23246Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccinesa prospective multi-center study |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1016%2Fj.heliyon.2023.e23246Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccinesa prospective multi-center study |
owl:sameAs |
https://semopenalex.org/work/W4389285594 |
ripekg:work/10.1016%2Fj.nmni.2025.101692Homologous and heterologous booster of COVID-19 vaccines: A systematic review and meta-analysis |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fj.heliyon.2023.e23246Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccinesa prospective multi-center study |